Prevalence of Hepatitis C Virus Genotypes in the Southern Region, Saudi Arabia

Abdullah M AlKahtani^{1*}, Meaad N Alsultan² Abdulrahim R Hakami³, Mohammad Alamri²

¹Department of Microbiology and Immunology, College of Medicine, King Khalid University, Abha 61421, Saudi Arabia

²Armed Forces Hospital Southern Region (AFHSR), Khamis Mushait, Saudi Arabia

³Clinical Laboratory Sciences Department, College of Applied Medical Sciences, King Khalid University, Abha 61481, Saudi Arabia

* Author for correspondence: Tel.: +966(0)17241-8123; email: abdalkahtani@kku.edu.sa

ABSTRACT: Aim: The aim of this study was to investigate the prevalence of HCV genotypes in the Southern Region, Saudi Arabia. **Materials & methods:** A total of 76 HCV-positive individuals were selected for this study, including 34 males and 42 females, both acute and chronic patients. All HCV isolates were genotyped by direct sequencing of the 5'UTR region. The Chemistry profile, viral load and history of blood transfusion were collected from the hospital record. **Results:** The most common genotype was gt 4 (48.7%) followed by gt 1 (34.2%) and gt 3 (14.5%). Genotype 2 (2.6%) was only found in elderly male individuals. Patients with history of blood transfusion showed a high percentage of genotype 1 compared to the total number of all patients with genotype 1 (23% and 11% respectively). Biochemical assay showed high level of ALT particularly in genotype 4. No significant relationship was observed between HCV genotype and AST level between genotypes. The viral load was higher in HCV patients received blood transfusion than other genotypes. **Conclusion:** The prevalence of genotypes in this study confirmed the observation of other investigations, but no link was found between sex and genotype. There might be an association between blood donation in the past and infections with genotype 1.

KEYWORDS: Chronicity, hepatitis c, genotype.

Introduction

Hepatitis C virus (HCV) is an enveloped, single-stranded RNA virus and belongs to Hepacivirus genus and *Flaviviridae* family [1]. HCV continues to be a worldwide critical public health concern which causes high morbidity and mortality. The virus is transmitted parenterally and uses CD8, SR-BI, claudin and occludin receptors for entry [2]. More than 170 million individuals are chronically infected with the virus worldwide with an estimation of more than 15 million seropositive individuals in the Middle East and North Africa, and this appears to be the highest prevalence with 3.6% infections [3]. It has been estimated that approximately 75%–85% of HCV-infected individuals develop chronic infection and up to half a million people die each year from hepatocellular carcinoma (HCC) and other related liver diseases [4,5].

There are about 80 recognized subtypes of HCV classified under at least six genotypes [6], and the prevalence is linked with geographical distribution [7]. The genetic diversity of the virus (quasi-species) suggests that more novel subtypes will be discovered. It has been hypothesized that HCV genotypes correlate with a varying degree of disease severity. Specific HCV genotypes were linked with liver steatosis, hepatic reactivation and liver fibrosis [8,9]. Genotype 1 is associated with higher risk of cirrhosis, HCC development, and poor response to therapy [10]. Because of that, genotyping has become necessary in the clinical analysis of patients with hepatitis C, to monitor therapeutic response and duration of treatment [11].

Despite that epidemiological data on HCV in Saudi Arabia is deficient [12,13] and also limited by small sample size [14], it has been speculated that viral hepatitis is highly endemic in the southwestern region in Saudi Arabia [15]. However, estimating the overall prevalence of HCV in the country is difficult due to lack of more studies in different geographical regions [16] with conflicting results regarding the actual prevalence [17]. It was identified that genotype 4 is the most predominant in Saudi Arabia followed by genotype 1 [18–20]. The nucleotide conservation was 92% and 95.5% respectively [21]. Subtypes 4a and 1b showed the highest level of nucleotides variation [22].

HCV is characterized by the emergence of resistance associated substitutions that renders the virus less susceptible to the direct-acting antiviral agents [23]. Better

understanding of the risk factors could support the development of targeted strategies to reduce HCV infection and disease severity. For example, a lower rate of sustained virologic response (SVR) was found in patients infected with the subtype 4r more than the other subtypes [24]. More studies with large number of samples are needed to examine the role of circulating subtypes in disease severity.

A recent study suggested that genotype 4 in Saudi Arabia has declined [25,26]. In addition, data on HCV genotyping in different Saudi Arabian regions is still scarce and this necessitates further investigations. The aim of this study is to determine the prevalence of HCV genotypes in acute and chronic patients in the Southern Region of Saudi Arabia.

Materials & methods

- **Patients selection**

A total of 76 HCV-positive patients from different cities in the Southern Region (34 males and 42 females; aged: 20-79 y) seen from 2016 to 2017 at the Armed Forces Hospital Southern Region (AFHSR) were enrolled in this study. Diagnosis of chronic hepatitis C was made according to the AFHSR Guideline on the Prevention and Treatment of Hepatitis C.

- **Detection of HCV antibodies**

Anti-HCV antibodies in patients' sera were qualitatively screened using a chemiluminescent microparticle immunoassay (CMIA-ARCHITECHT3; ABBOTT). Recombinant blot immunoassay (RIBA) were performed using Line ImmunoAssay for the detection of anti-HCV antibodies in human serum which was performed according to the manufacturer instructions (INNO-LIA HCV Score). Seropositive samples were examined for liver function tests, direct bilirubin levels and processed for genotyping determination.

- **Biochemistry profile**

Blood samples were collected in plain tubes and centrifuged for 10min at 3000rpm. Patients' sera were tested for biochemistry profile according to manufacturer's instructions using the fully automated machine (Beckman Unicel DxC 8000) in which

the level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) and direct bilirubin were determined.

- **Genotyping of HCV**

For HCV genotyping and HCV-RNA quantitative determination, 10ml of EDTA-anticoagulated blood were collected and transported promptly to Bioscientia Lab (Germany) on the same day of collection. Briefly, cobas® HCV GT assay (Roche Diagnostics) was run on the cobas 4800 system for HCV genotyping, which relies on direct sequencing of the NS5B gene on AB capillary sequencing system.

- **Statistical analysis**

Data were analyzed using GraphPad Prism, version 7.04 (GraphPad Software, CA, USA). The results of liver function tests are presented as the mean and percentage of overall patients infected with a specific genotype.

- **Ethics statement**

The project and data written were approved by the Ethics Committee of the College of Medicine, King Khalid University (KKU) and from AFHSR.

Results

- **Chemistry profile and immunoassays**

A total of 76 diagnosed HCV positive cases were confirmed by RIBA and selected for biochemistry profile for liver function tests, quantitative determination of HCV RNA and HCV genotyping. Of the 76 patients included in the study, 34 males (45%) and 42 females (55%) were all Saudi Arabian (20–79 years).

From different clinics at AFHSR, 76 patients were selected for enzyme immunoassay. Table 1 and Figure 1 show the percentage and the mean of AST and ALT, which are

important markers of hepatocytes injury. The liver function tests were determined for all HCV-seropositive patients. Patients were further investigated using chemiluminescent microparticle immunoassay (CMIA) and RIBA. Thirty patients (39%) were asymptomatic and showed normal biochemistry profile, while nearly 46% of the all patients showed a significant positive relationship between different HCV genotypes (specifically genotype 4) and the abnormal level of AST and ALT. However, no relationship was found between HCV infected individuals and the level of direct bilirubin and alkaline phosphatase (data not shown). Seventy-six positive patients were further investigated for genotyping and quantitative determination of the viral load for follow up.

- **The most common HCV genotype**

To determine the circulating HCV isolates, seropositive samples were genotyped. Out of 76 patients, 34.2% were genotype 1, 2.6% genotype 2, 14.5% genotype 3 and the highest of all 48.6% were genotype 4 (Table 2). In this study, HCV genotype 4 was the major genotype at least among this group of Saudi Arabian patients.

- **Age, gender and genotype**

Patients' sex and age were considered in the analysis of HCV genotypes. We then analyzed gender-related differences observed between the genotypes as shown in Figure 2 and Table 3. Genotypes 1, 3 and 4 were higher in females than males, possibly due to a higher prevalence of blood transfusion among women than men. The association between age and genotype is rather more interesting. In order to investigate the relationship between age and genotypes, Figure 3 and Table 4 summarize the overall association between age group and all tested HCV genotypes. Two male patients were genotype 2 positive; 70 and 75 years old. The rest of genotypes were found in young as well as elderly patients (Figure 3 and Table 4). However, genotype 3 was only seen in patients in their thirties and fifties.

- **Blood donation and HCV infections**

Sixty-three patients (82.9%) were non-transfusion recipients, while the rest (13 patients) have been subjected to blood transfusion in the past. All four genotypes

found in this investigation were considered in the analysis of blood transfusion. Genotype 4 was highest among non-transfusion patients. However, genotype 1 was the most prevalent among blood transfusion recipients (Figure 4).

Discussion

Data on the prevalence of circulating HCV strains in the Southern Region, Saudi Arabia, is limited. Determination of HCV genotypes has become crucial for the the assessment of clinical course and administration of antiviral drugs. Our investigation attempted to give insight towards the actual genotypes present in the region and to assess the varied epidemiology of the genotypes. HCV chronic patients were followed up by determining the viral load quantitatively. Samples with no viral load determined were either acute or from different clinics (Table 1).

More than one-third of patients were asymptomatic with normal liver enzymes. Both ALT and AST parameters (Table 1) showed significant differences between HCV genotypes. Many studies have shown that HCV genotype 1 is linked with severe liver disease and elevated liver enzymes [27]. It has been estimated that around 25% of chronic hepatitis C have normal ALT level [28]. However, the level of ALT is known to be fluctuating in patients with chronic hepatitis C and flares of disease activity [29].

Al-Raddadi *et. al.* 2017 claimed that the prevalence of HCV in Saudi Arabia is among the lowest worldwide, but the infection rate found in this study suggests that the prevalence could be higher than expected. A previous study showed that 5.87% of Saudis were seropositive to HCV [30]. Moreover, it has been estimated that 21.3 million individuals in the Eastern Mediterranean countries are HCV carriers, similar to Europe and the Americas combined [31]. The rate of HCV infection among the Injecting Drug Users (IDUs) in Saudi Arabia is relatively high [32], and this demands preventive strategies for improved socioeconomic welfare.

A recent study in the Western Province showed that HCV genotype 1 is the most predominant [33]. In this study, we determined that HCV genotype 4 was the most common (48.7%) in the Southern Province. This finding is consistent with other studies [18–20,30,34] in which genotype 4 is widespread among the population.

Moreover, a previous investigation detected that 50% of Saudi Arabian patients were infected with genotype 4 [35]. However, their sample size (n=22) was less than the number of patients used in this study (n=76).

Among hundreds of patients visited AFHSR clinics during collection of samples for HCV assays, we found that the rate of infection in females is higher than males (55.3% vs. 44.7% respectively). Bawazir *et. al.* 2017 surveyed 630 HCV-infected Saudi patients, and found that 47.6% were males and 52.4% were females. Discrepancies exist in results regarding gender and pathogenesis [36]. This requires further evaluation to draw evidence-based conclusions. In this study, no association was found between sex and genotype. In consistency with our investigation, Al Traif *et al.* 2013 study has not found a relationship between gender and genotype.

Interestingly, we found that the least prevalent genotype was exclusive to elderly patients. Genotype 2 was only seen in patients above 70yrs old, despite the small sample size with this particular genotype. In addition, Farag *et. al.* 2015 investigated 20 Egyptians and 20 Saudi Arabian patients. They observed that genotype 2 was only detected in Saudi patients.

Patients in dialysis settings are vulnerable to HCV infection despite good hygienic measures [37]. This necessitates strict control precautions and preventive methods to minimize infection [38]. Here, we focused on the history of blood transfusion. The relationship between blood transfusion and the most common genotypes (gt 4 and gt 1 respectively) were examined. An interesting observation is that patients with history of blood transfusion showed a high percentage of genotype 1 compared to the total number of all patients with genotype 1. The percentage is more than double with genotype 1 than genotype 4 (23% and 11% respectively). One limitation is that the overall number of patients infected with genotype 4 is higher than genotype 1. Whether this is a coincidental observation or with a significant link, it is worth noting. Another surprising observation is that the first five patients with the highest viral load have all received blood transfusion. It is difficult to infer any conclusion with regards to these unexpected observations found with the transfused patients, but it is noteworthy to consider in future investigations.

Conclusion

Out of 76 HCV-positive patients, genotype 4 was the highest among all assessed genotypes. This result was consistent with other findings. No association was found between gender, age and genotype. Genotype 2 was only found in elderly patients aged 70 and 75 years old. Genotype 1 was common among transfused patients.

Future perspective

Future studies will focus on subtypes and phylogenetic studies with higher number of samples as well as to determine whether subtype 4d is more common than other subtypes or not [39]. The investigation will include the effect of low oxygen level on the severity of HCV infection [40] hence these patients live at high altitude. This will determine any interesting or rare mutations.

Financial and competing interests disclosure

The authors have no relevant affiliations or financial involvements with any organization or any financial interest with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

The authors state that they obtained appropriate institutional review board approval or have followed the principles outlined in the Declaration of Helsinki for all human or animal experimental investigations. In addition, for investigations involving human subjects, informed consent has been obtained from the participants involved.

Executive summary

The most common HCV genotype

- Genotype 4 was the most prevalent of all assessed HCV genotypes among 76 positive patients.

Gender and genotype

- No association was found between sex and genotype.

Association between blood donation and genotype 1

- The increased percentage of genotype 1 among those who have received blood donation in the past is interesting.

References

1. Simmonds P, Becher P, Bukh J, *et al.* ICTV Virus Taxonomy Profile: Flaviviridae. *J Gen Virol.* 98(1), 2–3 (2017).
2. Tong Y, Lavillette D, Li Q, Zhong J. Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. *Front Immunol.* 9, 1411 (2018).
3. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. *Hepatology.* 57(4), 1333–1342 (2013).
4. Chen SL, Morgan TR. The Natural History of Hepatitis C Virus (HCV) Infection. *Int J Med Sci.* 3(2), 47–52 (2006).
5. Michielsen PP, Francque SM, van Dongen JL. Viral hepatitis and hepatocellular carcinoma. *World J Surg Oncol.* 3, 27 (2005).
6. Hedskog C, Chodavarapu K, Ku KS, *et al.* Genotype- and Subtype-Independent Full-Genome Sequencing Assay for Hepatitis C Virus. *J. Clin. Microbiol.* 53(7), 2049–2059 (2015).
7. Messina JP, Humphreys I, Flaxman A, *et al.* Global Distribution and Prevalence of Hepatitis C Virus Genotypes. *Hepatology.* 61(1), 77–87 (2015).
8. Leandro G, Mangia A, Hui J, *et al.* Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. *Gastroenterology.* 130(6), 1636–1642 (2006).

9. Rumi MG, De Filippi F, La Vecchia C, *et al.* Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. *Gut*. 54(3), 402–406 (2005).
10. Ripoli M, Pazienza V. Impact of HCV genetic differences on pathobiology of disease. *Expert Rev Anti Infect Ther*. 9(9), 747–759 (2011).
11. Lindh M, Hannoun C. Genotyping of hepatitis C virus by Taqman real-time PCR. *J. Clin. Virol*. 34(2), 108–114 (2005).
12. Fallahian F, Najafi A. Epidemiology of hepatitis C in the Middle East. *Saudi J Kidney Dis Transpl*. 22(1), 1–9 (2011).
13. Aljumah AA, Abaalkhail F, Al-Ashgar H, *et al.* Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift. *Saudi J Gastroenterol*. 22(4), 269–281 (2016).
14. Osoba AO, Ibrahim M, Abdelaal MA, Al-Mowallad A, Al Shareef B, Hussein BA. Hepatitis C virus genotyping by polymerase chain reaction and DNA enzyme immunoassay among Saudi patients in the Western Province, Saudi Arabia. *Ann Saudi Med*. 20(5–6), 394–397 (2000).
15. Al Humayed SM, El-Mekki AA, Mahfouz AA. Hepatitis B virus infection in Aseer Region, south-western Saudi Arabia: a call for an immediate action against a preventable disease. *Public Health*. 146, 24–28 (2017).
16. Abdo AA, Sanai FM, Al-Faleh FZ. Epidemiology of viral hepatitis in Saudi Arabia: are we off the hook? *Saudi J Gastroenterol*. 18(6), 349–357 (2012).
17. Al-Raddadi RM, Dashash NA, Alghamdi HA, *et al.* Hepatitis C virus infection in Jeddah city, Saudi Arabia: Seroprevalence and knowledge. *J. Med. Virol*. 90(3), 526–531 (2018).
18. Abozaid SM, Shoukri M, Al-Qahtani A, Al-Ahdal MN. Prevailing genotypes of hepatitis C virus in Saudi Arabia: a systematic analysis of evidence. *Ann Saudi Med*. 33(1), 1–5 (2013).
19. Boriskin YS, Bakir TM, al-Aska AI, Booth JC. Is hepatitis C virus genotype 4 predominant in Saudi Arabia? *New Microbiol*. 22(3), 173–180 (1999).
20. Ghaderi-Zefrehi H, Gholami-Fesharaki M, Sharafi H, Sadeghi F, Alavian SM. The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis. *Hepat Mon*. 16(9), e40357 (2016).
21. Shier MK, El-Wetidy MS, Ali HH, Al-Qattan MM. Characterization of hepatitis C virus genotypes by direct sequencing of HCV 5'UTR region of isolates from Saudi Arabia. *PLoS ONE*. 9(8), e103160 (2014).
22. Shier MK, Iles JC, El-Wetidy MS, Ali HH, Al Qattan MM. Molecular characterization and epidemic history of hepatitis C virus using core sequences of isolates from Central Province, Saudi Arabia. *PLoS ONE*. 12(9), e0184163 (2017).

23. Sorbo MC, Cento V, Di Maio VC, *et al.* Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018. *Drug Resist. Updat.* 37, 17–39 (2018).
24. Fourati S, Rodriguez C, Hézode C, *et al.* Frequent antiviral treatment failures in patients infected with hepatitis C virus genotype 4, subtype 4r. *Hepatology.* (2018).
25. Abdel-Moneim AS, Bamaga MS, Shehab GMG, Abu-Elsaad A-ASA, Farahat FM. HCV infection among Saudi population: high prevalence of genotype 4 and increased viral clearance rate. *PLoS ONE.* 7(1), e29781 (2012).
26. Bawazir A, AlGusheri F, Jradi H, AlBalwi M, Abdel-Gader A-G. Hepatitis C virus genotypes in Saudi Arabia: a future prediction and laboratory profile. *Virol. J.* 14(1), 208 (2017).
27. Chakravarti A, Dogra G, Verma V, Srivastava AP. Distribution pattern of HCV genotypes & its association with viral load. *Indian J Med Res.* 133(3), 326–331 (2011).
28. Zeuzem S, Alberti A, Rosenberg W, *et al.* Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity. *Alimentary Pharmacology & Therapeutics.* 24(8), 1133–1149 (2006).
29. Strader DB, Wright T, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. *Hepatology.* 39(4), 1147–1171 (2004).
30. Fakeeh M, Zaki AM. Hepatitis C: prevalence and common genotypes among ethnic groups in Jeddah, Saudi Arabia. *Am. J. Trop. Med. Hyg.* 61(6), 889–892 (1999).
31. Ramia S, Eid-Fares J. Distribution of hepatitis C virus genotypes in the Middle East. *International Journal of Infectious Diseases.* 10(4), 272–277 (2006).
32. Alibrahim OA, Misau YA, Mohammed A, Faruk MB, Ss I. Prevalence of hepatitis C viral infection among injecting drug users in a Saudi Arabian hospital: A point cross sectional survey. *J Public Health Afr.* 9(1), 726 (2018).
33. El Hadad S, Al-Hamdan H, Linjawi S. Partial sequencing analysis of the NS5B region confirmed the predominance of hepatitis C virus genotype 1 infection in Jeddah, Saudi Arabia. *PLoS ONE.* 12(5), e0178225 (2017).
34. Shobokshi OA, Serebour FE, Skakni LI. Hepatitis C genotypes/subtypes among chronic hepatitis patients in Saudi Arabia. *Saudi Med J.* 24 Suppl 2, S87-91 (2003).
35. Al-Knawy B, Okamoto H, Ahmed El-Mekki A, *et al.* Distribution of hepatitis C genotype and co-infection rate with hepatitis G in Saudi Arabia. *Hepatology Research.* 24(2), 95–98 (2002).

36. Stroffolini T, Rapicetta M, Di Stefano R. Hepatitis C virus clearance and gender. *Gut*. 56(6), 884 (2007).
37. Khedmat H, Amini M, Ghamar-Chehreh ME, Agah S. Hepatitis C virus infection in dialysis patients. *Saudi J Kidney Dis Transpl*. 25(1), 1–8 (2014).
38. Hussein MM, Mooij JM. Methods used to reduce the prevalence of hepatitis C in a dialysis unit. *Saudi J Kidney Dis Transpl*. 21(5), 909–913 (2010).
39. Khan A, Al Balwi M, AlAyyar L, AlAbdulkareem I, Albekairy A, Aljumah A. Tracing the epidemic history of hepatitis C virus genotypes in Saudi Arabia. *Infect. Genet. Evol*. 52, 82–88 (2017).
40. Vassilaki N, Kalliampakou KI, Kotta-Loizou I, *et al*. Low Oxygen Tension Enhances Hepatitis C Virus Replication. *J. Virol*. 87(5), 2935–2948 (2013).

Table legends

Table 1. Percentage and mean of AST and ALT enzymes that are abnormal.

Table 2. Percentage of HCV genotypes (n=76).

Table 3. HCV genotypes variation among Saudi Arabian Females and Males.

Table 4. HCV genotypes distribution in different age group.

Table 5. Frequency of HCV genotypes and history of blood transfusion.

Figure legends

Figure 1. The percentage and mean of AST and ALT in all HCV genotypes determined.

Figure 2. HCV genotypes variation among Saudi Arabian Females and Males.

Figure 3. HCV genotypes distribution in different age group.

Figure 4. Frequency of HCV genotypes and percentage of patients who received blood transfusion.

Table 2. Percentage of HCV genotypes (n=76).		
HCV genotypes	Number of positive HCV	Percentage
1	26	34.2 %
2	2	2.6 %
3	11	14.5 %
4	37	48.7 %

Table 2. Percentage of HCV genotypes (n=76).		
HCV genotypes	Number of positive HCV	Percentage
1	26	34.2 %
2	2	2.6 %
3	11	14.5 %
4	37	48.7 %

Table 3. HCV genotypes variation among Saudi Arabian Females and Males.						
HCV genotypes	Female		Male		Total	
	No.	%	No.	%	No.	%
1	15	19.7	11	14.5	26	34.2
2	0	0	2	2.6	2	2.6
3	7	9.2	4	5.3	11	14.5
4	20	26.3	17	22.3	37	48.7
Total	42	55.3	34	44.7	76	100

Table 4. HCV genotypes distribution in different age group.

Age group	Female		Male		Total
	No.	%	No.	%	
0-20 y	0	0	1	100	1
20-40 y	10	45	12	55	22
40-60 y	24	71	10	29	34
60-80 y	8	42	11	58	19
Total	42	55	34	45	76

Table 5. Frequency of HCV genotypes and history of blood transfusion.

History of blood transfusion	HCV genotypes				Total / percentage
	1	2	3	4	
Yes	7	1	1	4	13 (17.1 %)
No	19	1	10	33	63 (82.9 %)

Figure 1 shows the level of AST and ALT versus HCV genotypes

Figure.2 Sex versus HCV genotypes

The frequency of HCV genotypes with sex. Figure shows the detailed values of the rate with the total and percentage.

M: Male; F: Female.

Figure 3. Age versus genotype. Genotypes (blue circles) were aligned with the age.

Figure 4. Frequency of HCV genotype and history of blood transfusion